Alzheimer's Disease Trial, Recruiting NCT06880406 Sponsor: Centre Hospitalier Universitaire de Nice Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06880406
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with memory or thinking difficulties:

  • You have been experiencing memory or thinking problems (either noticed by yourself or by others) for at least 6 months
  • Your condition has been assessed following current official French health authority (HAS) guidelines
  • You have had a spinal fluid (cerebrospinal fluid) test done at the study center and agree to allow leftover spinal fluid to be stored for research
  • You are willing and able to sign a consent form agreeing to take part
  • You are covered by French social security (or an equivalent scheme)

For the Alzheimer's group specifically:

  • You have been diagnosed with Alzheimer's disease based on specific 2024 guidelines, confirmed by certain markers found in your spinal fluid

For the non-Alzheimer's group specifically:

  • You have been diagnosed with mild or significant memory/thinking difficulties (not caused by Alzheimer's disease), confirmed by the absence of certain Alzheimer's markers in your spinal fluid

For healthy volunteers:

  • You are an adult
  • You have no history of neurological or psychiatric conditions
  • You have no concerns about your memory or thinking ability
  • You scored 27 out of 30 or higher on a standard memory test (MMSE)
  • You scored 0 on a standard assessment of daily functioning related to memory (CDR-SOB)
  • You are covered by French social security (or an equivalent scheme)

Who may not be able to join:

  • People who are considered vulnerable (confirm with trial site for the specific definition used)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aurélie MOUTON, MD,PhD, Centre Hospitalier Universitaire de Nice

Phone: 33492034778

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
1 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Mitochondrial oxygen consumption of peripheral blood cells; Mitochondrial oxygen consumption of peripheral blood cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov